The strong linear correlation between GZMK and PD-1 in breast cancer suggests a potential influence on T-cell differentiation and the T-cell receptor signaling pathway, offering a new therapeutic target for further exploration in breast cancer immunotherapy. This evidence concerns the gene PDCD1 and breast cancer.